Novo Nordisk Shares Plunge as Investors Disappoint With Growth Plan
Shares of Novo Nordisk fell after CEO Mike Doustdar presented a strategy that investors found lacking in concrete details to counter competition from Eli Lilly.
Eli Lilly
3 stories · 1 market · RSS
Email me new stories on Eli Lilly
Markets on Eli Lilly
Coverage vs. odds, last two weeks
How much the press wrote about Eli Lilly each day, and what its busiest market did over the same days.
Will Viking Therapeutics be acquired before 2027?
Price data
| Time | Chance of yes |
|---|---|
| now | 17% |
| 22 Sept, 19:10 UTC | 17% |
| 22 Sept, 17:54 UTC | 16% |
| 21 Sept, 17:36 UTC | 14% |
Stories
Viking's Obesity Drug Data Fuels Bets It Can Rival Lilly's Zepbound
Viking Therapeutics reports that patients maintained weight loss on its VK2735 drug, boosting investor confidence in its potential to compete with Eli Lilly.
Polymarket Will Viking Therapeutics be acquired before 2027? 17% +2